Climb Bio (CLYM) Competitors $2.23 -0.07 (-3.04%) As of 08/29/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock CLYM vs. MGTX, VIR, BCAX, MAZE, RLAY, SNDL, RZLT, KROS, TRML, and ORGOShould you be buying Climb Bio stock or one of its competitors? The main competitors of Climb Bio include MeiraGTx (MGTX), Vir Biotechnology (VIR), Bicara Therapeutics (BCAX), Maze Therapeutics (MAZE), Relay Therapeutics (RLAY), SNDL (SNDL), Rezolute (RZLT), Keros Therapeutics (KROS), Tourmaline Bio (TRML), and Organogenesis (ORGO). These companies are all part of the "pharmaceutical products" industry. Climb Bio vs. Its Competitors MeiraGTx Vir Biotechnology Bicara Therapeutics Maze Therapeutics Relay Therapeutics SNDL Rezolute Keros Therapeutics Tourmaline Bio Organogenesis Climb Bio (NASDAQ:CLYM) and MeiraGTx (NASDAQ:MGTX) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk. Which has higher earnings and valuation, CLYM or MGTX? Climb Bio has higher earnings, but lower revenue than MeiraGTx. MeiraGTx is trading at a lower price-to-earnings ratio than Climb Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioClimb BioN/AN/A-$73.90M-$0.70-3.19MeiraGTx$33.28M17.65-$147.79M-$2.04-3.58 Which has more volatility and risk, CLYM or MGTX? Climb Bio has a beta of -0.11, suggesting that its share price is 111% less volatile than the S&P 500. Comparatively, MeiraGTx has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Do analysts recommend CLYM or MGTX? Climb Bio presently has a consensus target price of $9.00, suggesting a potential upside of 303.59%. MeiraGTx has a consensus target price of $24.00, suggesting a potential upside of 228.77%. Given Climb Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Climb Bio is more favorable than MeiraGTx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Climb Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 2 Strong Buy rating(s) 3.33MeiraGTx 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CLYM or MGTX more profitable? Climb Bio has a net margin of 0.00% compared to MeiraGTx's net margin of -415.39%. Climb Bio's return on equity of -23.10% beat MeiraGTx's return on equity.Company Net Margins Return on Equity Return on Assets Climb BioN/A -23.10% -22.47% MeiraGTx -415.39%-314.44%-63.28% Does the media prefer CLYM or MGTX? In the previous week, Climb Bio had 1 more articles in the media than MeiraGTx. MarketBeat recorded 4 mentions for Climb Bio and 3 mentions for MeiraGTx. MeiraGTx's average media sentiment score of 1.78 beat Climb Bio's score of 0.94 indicating that MeiraGTx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Climb Bio 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MeiraGTx 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Do insiders and institutionals believe in CLYM or MGTX? 69.8% of Climb Bio shares are held by institutional investors. Comparatively, 67.5% of MeiraGTx shares are held by institutional investors. 0.8% of Climb Bio shares are held by company insiders. Comparatively, 7.5% of MeiraGTx shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. SummaryClimb Bio beats MeiraGTx on 12 of the 16 factors compared between the two stocks. Get Climb Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for CLYM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CLYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLYM vs. The Competition Export to ExcelMetricClimb BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$155.86M$3.06B$5.66B$9.84BDividend YieldN/A2.28%3.93%4.04%P/E Ratio-3.1920.9283.2726.61Price / SalesN/A200.54451.26176.28Price / CashN/A44.0537.7059.65Price / Book0.818.0710.556.59Net Income-$73.90M-$53.98M$3.27B$266.12M7 Day Performance-6.30%-0.88%0.42%0.16%1 Month Performance46.71%6.20%5.91%3.02%1 Year PerformanceN/A7.13%48.11%19.65% Climb Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLYMClimb Bio3.3276 of 5 stars$2.23-3.0%$9.00+303.6%N/A$155.86MN/A-3.199Gap UpMGTXMeiraGTx4.5638 of 5 stars$7.85+3.8%$24.00+205.7%+74.6%$608.18M$33.28M-3.85300News CoverageVIRVir Biotechnology3.3216 of 5 stars$4.38+0.5%$30.25+590.6%-40.5%$605.68M$74.21M-1.10580News CoverageAnalyst UpgradeBCAXBicara Therapeutics1.8146 of 5 stars$11.63+6.1%$32.25+177.3%N/A$598.01MN/A-3.6732MAZEMaze TherapeuticsN/A$13.23-1.9%$25.60+93.5%N/A$591.11M$167.50M0.00121News CoverageRLAYRelay Therapeutics2.2505 of 5 stars$3.41+0.3%$17.25+405.9%-46.9%$586.20M$10.01M-1.75330Trending NewsAnalyst ForecastAnalyst RevisionSNDLSNDL1.8664 of 5 stars$2.24+1.4%$4.00+78.6%+37.4%$580.73M$671.81M-8.302,516RZLTRezolute3.4502 of 5 stars$6.96+4.5%$12.20+75.3%+49.9%$579.39MN/A-6.0540News CoveragePositive NewsKROSKeros Therapeutics3.3762 of 5 stars$15.17+6.6%$30.00+97.8%-66.4%$577.96M$3.55M48.94100News CoveragePositive NewsHigh Trading VolumeTRMLTourmaline Bio2.318 of 5 stars$23.06+2.7%$50.14+117.4%+35.7%$576.90MN/A-6.7244Positive NewsORGOOrganogenesis4.2306 of 5 stars$4.47-2.4%$7.50+67.8%+77.6%$567.06M$429.31M-31.93950News CoveragePositive News Related Companies and Tools Related Companies MeiraGTx Competitors Vir Biotechnology Competitors Bicara Therapeutics Competitors Maze Therapeutics Competitors Relay Therapeutics Competitors SNDL Competitors Rezolute Competitors Keros Therapeutics Competitors Tourmaline Bio Competitors Organogenesis Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLYM) was last updated on 8/30/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored“HELIOS”: My No. 1 Investment of the 2020sA mysterious new energy technology — backed by Nvidia, Google, and even legendary investors like Stanley Druck...Stansberry Research | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Climb Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Climb Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CLYM Stock Alerts